The $700M upfront transforms Nurix's balance sheet and funds substantial clinical development without dilution. Traders should watch for upcoming clinical data readouts in CLL, MS, and CSU which will drive the near-term binary outcomes. The deal significantly reduces risk given Roche's global infrastructure and credibility.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 8 $15.64entry
- T+1 · 5mo ago 0.00%α +0.29% · $15.64
- T+5 · 5mo ago +8.95%α +6.84% · $17.04
- T+20 · 4mo ago +53.71%α +52.08% · $24.04
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral BTK degrader, across oncology, immunology, and neurology. Nurix receives $700M upfront and is eligible for up to $2.3B in milestones, with 50/50 U.S. profit sharing and tiered royalties on ex-U.S. sales. This deal provides significant non-dilutive capital, validates Nurix's platform, and de-risks expansion into large indications like multiple sclerosis and chronic spontaneous urticaria, making it a transformative event for the company.
Key Financial Metrics
Key Facts
- Nurix receives $700 million upfront cash payment from Roche.
- Total potential milestone payments up to $2.3 billion.
- Development costs shared 40% Nurix / 60% Roche.
- U.S. profits and losses split equally; Nurix receives royalties (low- to high-teens) on ex-U.S. sales.
- Development plan includes pivotal CLL trials and Phase 2 trials in multiple sclerosis and chronic spontaneous urticaria.
- Bexobrutideg is a brain-penetrant oral BTK degrader with potential advantages over BTK inhibitors.
- Goldman Sachs acted as exclusive financial advisor to Nurix.
Financial Impact
$700M upfront cash payment; up to $2.3B total milestones; 50/50 U.S. profit share; tiered ex-U.S. royalties in low- to high-teens
Risk Factors
- Clinical trial execution and regulatory approval risks across multiple indications
- Shared development costs (40% Nurix) may strain resources if timelines extend
- Potential for HSR antitrust review delays or conditions
- Competitive landscape from existing BTK inhibitors and emerging degraders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307775 |
Track record
33 reports on NRIX
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers